SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024.

加利福尼亚州南旧金山，2023年12月19日（环球通讯社）--Harpoon Therapeutics，Inc.（纳斯达克：HARP），一家开发新型T细胞接合器的临床阶段免疫治疗公司，今天宣布，在美国临床肿瘤学会泌尿生殖系统癌症研讨会（ASCO-GU）上，将于2024年1月25日至27日在加利福尼亚州旧金山举行的1/2期临床试验评估HPN328在小细胞肺癌（SCLC）和其他神经内分泌肿瘤类型中的最新中期单一疗法数据的抽象接受和即将进行的快速口头介绍。

HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells. Details of the ASCO-GU presentation are as follows: Title: “Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting T-Cell Engager in Patients with Neuroendocrine Prostate Cancer (NEPC) and other Neuroendocrine Neoplasms (NEN)” Abstract number: 121 Session: Rapid Oral Abstract Session A: Prostate Cancer Session track: Prostate Cancer - Advanced | Prostate Cancer - Localized Session date & time: Thursday, January 25, 2024 at 4:15 PM – 5:00 PM PST Presenter: Himisha Beltran, M.D.

HPN328靶向δ样配体3（DLL3），源自Harpoon专有的三特异性T细胞激活构建体（TriTAC®）平台，该平台旨在募集患者自身的免疫细胞以杀死肿瘤细胞。ASCO-GU演讲的详细信息如下：标题：“HPN328的1/2期研究的中期结果，HPN328是一种三特异性半衰期（T1/2）延长的DLL3靶向T细胞参与者，用于神经内分泌前列腺癌（NEPC）和其他神经内分泌肿瘤（NEN）”摘要编号：121次会议：快速口头摘要会议a：前列腺癌会议轨道：前列腺癌-晚期|前列腺癌-本地化会议日期和时间：2024年1月25日星期四下午4:15–5:00 PST主持人：医学博士Himisha Beltran。

| Dana-Farber Cancer Institute Location: Level 3, Ballroom | Livestream The presentation will also be available on Harpoon’s website under Publications following the session. For more details about the ASCO-GU Annual Meeting, please visit: https://conferences.asco.org/gu/attend About HPN328HPN328 targets delta-like canonical Notch ligand 3 (DLL3) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s .

|达纳·法伯癌症研究所地点：3楼，宴会厅| Livestream会议结束后，演示文稿也将在Harpoon的网站上发布。有关ASCO-GU年会的更多详细信息，请访问：https://conferences.asco.org/gu/attend大约HPN328HPN328靶向delta样经典Notch配体3（DLL3），基于Harpoon专有的三特异性T细胞激活构建体（TriTAC®）平台，旨在招募患者。